Dermatomyositis
Aug 18, 2026
AstraZeneca Discontinues Phase III eVOLVE-Lung02 Trial of Volrustomig in Metastatic NSCLC; argenx Announces Favorable Topline Results from Phase 3 ALKIVIA Study of Efgartigimod; Bristol Myers Squibb’s ZENBEXUS Receives U.S. FDA Accelerated Approval in Combination with Daratumumab and Dexamethasone for Multiple Myeloma; Zealand Pharma Secures USD 100 Million in Royalty Financing Through Agreement with Royalty Pharma for Rusfertide; PTC Advances Rare Disease Strategy with Acquisition of ST-920 Fabry Disease Program
AstraZeneca Ends eVOLVE-Lung02 Phase III Trial Evaluating Volrustomig Plus Chemotherapy AstraZeneca has decided to discontinue the Phase III eVOLVE-Lung02 trial, which was assessing volrustomig in combination with chemotherapy as a first-line treatment for patients with metastatic non-small cell lung cancer (mNS...
Read More...
Aug 17, 2026
TYK2 Inhibitors: The Competitive Race Fueling the Next Generation of Autoimmune Therapies
Summary TYK2 inhibitors are emerging as a major class of oral immunology therapies, aiming to combine biologic-level efficacy with the convenience of a pill and fewer safety concerns than broader JAK inhibitors. Bristol Myers Squibb’s SOTYKTU remains the first approved TYK2 inhibitor and expanded its positio...
Read More...
May 27, 2025
Unraveling the Complexities of Dermatomyositis Treatment: A Comprehensive Review and Future Perspectives
Dermatomyositis, characterized by muscle weakness and skin symptoms, is a condition linked to increased morbidity and mortality. It markedly affects the quality of life for individuals afflicted, as well as the well-being of their families. According to DelveInsight’s estimates, in 2023, there were nearly 72K diagn...
Read More...
Jan 09, 2024
Merck to Acquire Harpoon Therapeutics; Novo Nordisk Enters Into Collaborations with Omega Therapeutics and Cellarity; AbbVie’s Lutikizumab’s Phase II Trial Result for Hidradenitis Suppurativa; Abbisko’s CSF-1R Inhibitor Pimicotinib (ABSK021); Cabaletta Bio’s CABA-201; FDA Grants Fast Track” Designation for Soligenix’s Dusquetide
Lutikizumab Showed Positive Results in a Phase II Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase III AbbVie has reported the results of Phase II trials indicating that adults experiencing moderate to severe hidradenitis suppurativa, and who had previously not respon...
Read More...
Jul 17, 2023
Analyzing Strategies in Polymyositis and Dermatomyositis Treatment
Inflammatory myositis refers to a group of disorders affecting the muscles and may be associated with different causes such as infection, drug toxicity, trauma, and autoimmune diseases. The most prominent cause of myositis is an autoimmune disease, typically known as idiopathic inflammatory myopathy (IIM). The indi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
